CN1682910A - 一种中成药或保健食品组合物及其应用 - Google Patents
一种中成药或保健食品组合物及其应用 Download PDFInfo
- Publication number
- CN1682910A CN1682910A CNA2005100491038A CN200510049103A CN1682910A CN 1682910 A CN1682910 A CN 1682910A CN A2005100491038 A CNA2005100491038 A CN A2005100491038A CN 200510049103 A CN200510049103 A CN 200510049103A CN 1682910 A CN1682910 A CN 1682910A
- Authority
- CN
- China
- Prior art keywords
- test
- health
- food composition
- chinese patent
- patent medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 235000013402 health food Nutrition 0.000 title claims abstract description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 19
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 18
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 18
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 18
- 206010020772 Hypertension Diseases 0.000 claims abstract description 17
- 244000068988 Glycine max Species 0.000 claims abstract description 16
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 16
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 16
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 16
- 229940057059 monascus purpureus Drugs 0.000 claims abstract description 16
- 201000005577 familial hyperlipidemia Diseases 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims description 24
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 15
- 244000113306 Monascus purpureus Species 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 15
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 22
- 241000700159 Rattus Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 241000053227 Themus Species 0.000 description 7
- 239000013642 negative control Chemical group 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 4
- 206010061619 Deformity Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical group C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960001441 aminoacridine Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical group O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010050106 Paroxysmal arrhythmia Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 208000002312 Teratozoospermia Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- -1 anthracene ester Chemical class 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 229940098421 anthraquinone glycoside Drugs 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960001577 dantron Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
剂量(g/kg) | 雌性 | 雄性 | 动物反应 | LD50(g/kg体重) | |||
动物数 | 死亡数 | 动物数 | 死亡数 | ||||
SD大鼠 | 1.002.154.6410.0 | 5555 | 0000 | 5555 | 0000 | 正常正常正常正常 | >10 |
ICR小鼠 | 1.002.154.6410.0 | 5555 | 0000 | 5555 | 0000 | 正常正常正常正常 | >10 |
剂量(μg/皿) | 回变菌落数(X±SD) | ||||||||
TA97a | TA98 | TA100 | TA102 | ||||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | ||
受试物 | 084020010005000 | 156.3±11.59146.7±23.18160.0±12.00156.7±11.93152.3±4.04162.3±11.93 | 174.7±5.77172.3±11.93168.3±8.39165.0±7.55162.3±8.50172.7±10.07 | 30.7±2.3130.3±2.0831.3±2.5229.7±2.8930.7±3.2130.7±2.52 | 37.7±3.5139.0±2.6539.7±4.0437.3±3.2141.0±2.6540.0±2.65 | 166.7±14.01157.7±8.39161.3±6.03160.3±11.59167.0±12.53157.3±7.23 | 179.0±12.53184.3±7.23190.3±13.58187.3±6.43186.3±11.50186.7±13.61 | 259.7±11.59262.0±18.33263.7±18.01161.7±12.34256.0±11.14255.0±10.44 | 295.7±6.51287.3±14.74293.7±17.56290.3±12.10315.0±6.56296.7±10.07 |
9AA | 25 | >1000 | |||||||
2.7AF | 20 | 330 | |||||||
NaN3 | 1.5 | >1000 | |||||||
2AAF | 10 | >1000 | >1000 | >1000 | |||||
MMC | 0.5 | >1000 | |||||||
1.8HAQ | 25 | >1000 |
受试物 | 剂量(μg/皿) | 回变菌落数(X±SD) | |||||||
TA97a | TA98 | TA100 | TA102 | ||||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | ||
受试物 | 084020010005000 | 152.0±6.00154.0±7.94155.7±11.85151.0±16.64160.3±8.62162.7±10.07 | 177.0±10.44166.7±10.26162.3±11.93174.7±9.45166.0±8.89176.0±8.72 | 31.0±2.6530.0±2.0031.0±1.7331.7±2.0834.0±2.6530.0±1.00 | 39.0±2.6539.3±4.1641.3±1.5338.7±3.0637.7±3.0638.0±2.00 | 170.7±14.74161.3±12.22158.3±13.87153.7±10.21157.3±6.03165.7±20.98 | 175.3±12.34164.3±14.57157.0±5.57160.3±12.01170.0±9.85175.3±15.14 | 248.7±13.01259.0±10.44272.7±8.33257.7±14.50258.7±13.32260.3±15.50 | 296.0±7.00293.0±7.81306.0±5.29295.7±6.51295.0±15.39297.7±9.45 |
9AA | 25 | >1000 | |||||||
2.7AF | 20 | 321 | |||||||
NaN3 | 1.5 | >1000 | |||||||
2AAF | 10 | >1000 | >1000 | >1000 | |||||
MMC | 0.5 | >1000 | |||||||
1.8HAQ | 25 | >1000 |
性别 | 组别 | 剂量(g/kg) | 鼠数 | 嗜多染红细胞数 | 微核细胞数 | 微核率(‰) |
雌 | 阴性对照 | 0.0 | 5 | 5000 | 9 | 1.8 |
受试物 | 2.5 | 5 | 5000 | 7 | 1.4 | |
5.0 | 5 | 5000 | 9 | 1.8 | ||
10.0 | 5 | 5000 | 8 | 1.6 | ||
环磷酰胺 | 0.04 | 5 | 5000 | 74 | 14.8* | |
雄 | 阴性对照 | 0.0 | 5 | 5000 | 7 | 1.4 |
受试物 | 2.5 | 5 | 5000 | 10 | 2.0 | |
5.0 | 5 | 5000 | 8 | 1.6 | ||
10.0 | 5 | 5000 | 9 | 1.8 | ||
环磷酰胺 | 0.04 | 5 | 5000 | 76 | 15.2* |
组别 | 剂量(g/kg) | 鼠数 | 观察***数 | 畸形***数 | 小计 | 微核率(‰) | ||||||
无定性 | 无钩 | 折叠 | 胖头 | 香蕉 | 双头 | 双尾 | ||||||
受试物 | 0.0 | 5 | 5000 | 67 | 4 | 1 | 72 | 1.44 | ||||
2.5 | 5 | 5000 | 71 | 6 | 1 | 78 | 1.56 | |||||
5.0 | 5 | 5000 | 75 | 3 | 2 | 80 | 1.60 | |||||
10.0 | 5 | 5000 | 68 | 3 | 1 | 72 | 1.44 | |||||
MMC | 0.002 | 5 | 5000 | 246 | 24 | 20 | 20 | 18 | 328 | 6.56* |
性别 | 剂量(g/kg) | 鼠数 | 始重(g) | 第一周(g) | 第二周(g) | 第三周(g) | 第四周(g) |
雌性 | 0.01.252.53.3 | 10101010 | 77.6±4.877.7±4.477.7±5.376.7±5.7 | 123.4±8.7120.9±6.6123.7±7.6121.1±6.4 | 159.9±10.0159.3±9.4154.3±7.2155.4±7.3 | 178.1±10.5181.7±9.8180.1±9.4179.9±9.2 | 205.6±10.4211.9±11.6207.6±12.5206.1±9.8 |
雄性 | 1.01.252.53.3 | 10101010 | 80.6±6.180.8±5.480.6±4.080.8±5.0 | 140.9±10.6138.6±8.8137.0±5.0135.9±7.4 | 196.5±14.1190.1±10.3190.5±13.6184.6±15.9 | 240.3±16.8235.5±17.2241.6±15.0232.6±24.9 | 275.9±22.6260.3±17.6274.8±15.5268.3±24.1 |
性别 | 剂量(g/kg) | 鼠数 | 增重(g) | 进食量(g) | 食物利用率(g) |
雌性 | 0.01.252.53.3 | 10101010 | 128.0±9.3134.2±12.1129.9±10.3129.4±13.1 | 534.0±23.2535.5±18.6536.7±24.4539.6±17.5 | 23.97±1.3725.04±1.7824.19±1.3223.98±2.27 |
雄性 | 1.01.252.53.3 | 10101010 | 195.3±21.2179.5±18.7194.2±15.4187.5±25.0 | 686.3±32.5666.7±23.6685.3±21.8669 3±26.5 | 28.40±2.1026.88±2.1328.30±1.3627.93±2.82 |
性别 | 剂量(g/kg) | 鼠数 | 红细胞(×1012/L) | 血红蛋白(g/L) | 白细胞(×109/L) | 白细胞分类(%) | ||
淋巴 | 中性 | 其它 | ||||||
雌性 | 0.01.252.53.3 | 10101010 | 8.55±0.337.93±0.338.15±0.647.89±0.38 | 156.17.4155.4±4.4156.9±4.9157.9±6.7 | 14.15±2.9311.01±2.0411.30±3.7113.86±3.50 | 79.279 280.084.0 | 19.420.119.014.0 | 1.40.71.02.0 |
雄性 | 0.01.252.53.3 | 10101010 | 8.13±0.348.99±1.118.80±1.688.32±1.46 | 155.9±7.7172.9±16.8172.8±24.7163.8±19.0 | 13.48±3.5112.30±2.9413.85±3.3513.46±1.82 | 79.574.378.581.1 | 19.424.319.415.5 | 1.11.42.13.4 |
性别 | 剂量(g/kg) | 鼠数 | ALT(IU/L) | TP(g/L) | ALB(g/L) | TG(mmol/L) | Chol(mmol/L) | Glu(mmol/L) | Urea(mmol/L) | CR(umol/L) |
雌性 | 0.01.252.53.3 | 10101010 | 60.3±7.069±11.161.9±9.356.1±7.4 | 68.0±3.569.4±4.770.9±6.165.4±3.7 | 36.3±1.838.5±2.239.2±3.635.8±1.6 | 0.46±0.360.37±0.200.28±0.110.31±0.21 | 1.84±0.271.90±0.191.70±0.311.76±0.29 | 4.22±0.573.90±0.574.06±0.653.73±0.45 | 5.63±0.966.41±1.096.04±0.736.09±1.22 | 48.6±3.052.6±3.350.7±6.345.8±7.0 |
雄性 | 0.01.252.53.3 | 10101010 | 88.3±10.381.0±14.681.3±9.989.2±11.2 | 62.7±3.163.7±1.562.8±2.567.0±3.0 | 34.9±1.234.4±1.134.0±1.436.1±1.6 | 0.50±0.110.41±0.140.37±0.160.52±0.21 | 1.78±0.381.57±0.381.57±0.151.71±0.36 | 4.13±0.253.28±0.783.62±0.693.79±0.67 | 6.23±1.046.47±1.306.48±0.776.42±0.87 | 46.3±5.150.4±7.648.1±3.548.7±4.2 |
性别 | 剂量(g/kg) | 鼠数 | 肝体比(%) | 肾体比(%) | 脾体比(%) | 睾体比(%) |
雌性 | 0.01.252.53.3 | 10101010 | 3.43±0.153.22±0.163.23±0.173.31±0.36 | 0.90±0.080.92±0.060.93±0.050.95±0.08 | 0.26±0.020.25±0.050.24±0.020.26±0.07 | |
雄性 | 0.01.252.53.3 | 10101010 | 3.37±0.223.41±0.153.30±0.183.37±0.18 | 0.97±0.040.97±0.071.00±0.050.98±0.04 | 0.23±0.040.25±0.020.22±0.030.23±0.03 | 0.94±0.070.94±0.120.98±0.070.96±0.08 |
项目 | 对照组(n=50) | 试食组(n=50) | ||
试食前 | 试食后 | 试食前 | 试食后 | |
红细胞(×1012/L)白细胞(×109/L)血红蛋白(g/L)血清总蛋白(g/L)白蛋白(g/L)谷丙转氨酶(μ/L)谷草转氨酶(μ/L)血糖(mmol/L)尿素氮(mmol/L)肌酐(μmol/L) | 4.61±0.375.01±0.65142.14±14.1579.92±3.1647.29±2.5728.14±11.9226.34±6.704.33±0.363.71±0.7067.98±13.93 | 4.57±0.325.10±0.55141.94±13.2779.59±2.3146.17±1.8325.92±8.1624.06±7.704.48±0.303.55±0.5366.72±9.15 | 4.61±0.465.68±1.25142.62±16.6279.34±3.0547.16±2.3229.88±13.6726.90±8.464.28±0.403.78±0.8967.70±13.06 | 4.62±0.425.24±0.83142.84±16.2679.37±2.3046.13±1.1226.84±9.4622.88±7.284.42±0.263.74±0.7366.60±7.73 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100491038A CN1325089C (zh) | 2005-02-06 | 2005-02-06 | 一种中成药或保健食品组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100491038A CN1325089C (zh) | 2005-02-06 | 2005-02-06 | 一种中成药或保健食品组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1682910A true CN1682910A (zh) | 2005-10-19 |
CN1325089C CN1325089C (zh) | 2007-07-11 |
Family
ID=35262529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100491038A Expired - Fee Related CN1325089C (zh) | 2005-02-06 | 2005-02-06 | 一种中成药或保健食品组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1325089C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITPI20110038A1 (it) * | 2011-04-08 | 2012-10-09 | Funcional Food Res S R L | Composizione alimentare funzionale a base di farina. |
CN102940209A (zh) * | 2011-08-15 | 2013-02-27 | 曾广宁 | 一种预防和清除肝脏中多余脂肪的保健食品及其制备方法 |
CN108186920A (zh) * | 2018-02-02 | 2018-06-22 | 金华寿仙谷药业有限公司 | 一种具有辅助降血脂功效的药物组合物及其制备方法 |
CN110170027A (zh) * | 2019-04-23 | 2019-08-27 | 广东健信制药股份有限公司 | 一种山楂红曲粉丸剂及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1216613C (zh) * | 2001-07-05 | 2005-08-31 | 深圳太太药业有限公司 | 一种具有调节血脂作用的保健品及制备方法 |
CN1248700C (zh) * | 2003-04-14 | 2006-04-05 | 李朝晖 | 预防和治疗高血脂症的保健品 |
CN1287807C (zh) * | 2003-09-06 | 2006-12-06 | 郭凌云 | 一种能调节人体血脂的保健食品 |
-
2005
- 2005-02-06 CN CNB2005100491038A patent/CN1325089C/zh not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITPI20110038A1 (it) * | 2011-04-08 | 2012-10-09 | Funcional Food Res S R L | Composizione alimentare funzionale a base di farina. |
WO2012137163A1 (en) * | 2011-04-08 | 2012-10-11 | Funcional Food Research S.R.L. | Flour-based functional food |
CN102940209A (zh) * | 2011-08-15 | 2013-02-27 | 曾广宁 | 一种预防和清除肝脏中多余脂肪的保健食品及其制备方法 |
CN102940209B (zh) * | 2011-08-15 | 2013-12-18 | 曾广宁 | 一种预防和清除肝脏中多余脂肪的保健食品及其制备方法 |
CN108186920A (zh) * | 2018-02-02 | 2018-06-22 | 金华寿仙谷药业有限公司 | 一种具有辅助降血脂功效的药物组合物及其制备方法 |
CN110170027A (zh) * | 2019-04-23 | 2019-08-27 | 广东健信制药股份有限公司 | 一种山楂红曲粉丸剂及其制备方法 |
CN110170027B (zh) * | 2019-04-23 | 2021-06-29 | 广东健信制药股份有限公司 | 一种山楂红曲粉丸剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1325089C (zh) | 2007-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100337662C (zh) | 一种治疗高血脂症的药物组合物及其制备方法 | |
CN1457808A (zh) | 一种铁皮石斛复方制剂及制备和应用 | |
CN1301666C (zh) | 一种能增强免疫力的保健食品及其制备方法 | |
CN1646150A (zh) | 经加工的人参提取物及从中分离的皂角甙的新用途 | |
WO2006081739A1 (fr) | Composition servant à traiter ou à prévenir l'hyperlipémie, l'hypertension ou l'infiltration lipidique hépatique | |
CN1682910A (zh) | 一种中成药或保健食品组合物及其应用 | |
CN1305405C (zh) | 一种能辅助降血糖、辅助降血脂的保健食品及其制备方法 | |
CN1255138C (zh) | 一种对酒精性肝损伤具有辅助保护作用的中药制剂及制备方法 | |
CN102188486B (zh) | 一种防治脂肪肝的药物组合物及其制备方法 | |
CN1785054A (zh) | 一种具有抗氧化功能的保健食品及其制备工艺 | |
CN1191082C (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN1297290C (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN101036722A (zh) | 一种缓解疲劳、改善男性更年期综合征的保健食品及制备 | |
CN1738633A (zh) | 来自药用植物的抗肥胖组分及其组合物 | |
CN1099293C (zh) | 一种降血脂制剂及其工艺和应用 | |
CN1686519A (zh) | 一种防止酒精性肝损伤的药物组合 | |
CN1201774C (zh) | 一种治疗高脂血症的药物 | |
CN1319588C (zh) | 治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 | |
CN1231255C (zh) | 以南瓜为主要原料制备的治疗便秘的胶囊配方及配制方法 | |
CN1218701C (zh) | 螺甾醇类甾体皂苷在制备治疗心脑血管疾病药物中的应用 | |
CN1282470C (zh) | 一种抗抑郁中药及其制备方法 | |
CN101062374A (zh) | 一种治疗癌症的中药组合物胶囊的制备方法及其产品 | |
CN1546533A (zh) | 猴头菌硫酸酯蛋白多糖、其制备方法和以该化合物为活性成分的药物组合物 | |
KR100573592B1 (ko) | 비만치료·억제용 백모근 추출물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XINFU PHARMACEUTICAL IND CO., LTD., HANGZHOU Effective date: 20070907 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070907 Address after: 311300 Jin Town, Zhejiang City, Ling'an Province Patentee after: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311305 Ling'an Economic Development Zone, Zhejiang, Hangzhou Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 311300 Jin Town, Zhejiang City, Ling'an Province Patentee after: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311300 Jin Town, Zhejiang City, Ling'an Province Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20160623 Address after: Hangzhou City, Zhejiang province 311300 Ling'an City Kam South Street No. 9 Gua fan Patentee after: HANGZHOU XINFU SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 311300 Jin Town, Zhejiang City, Ling'an Province Patentee before: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070711 Termination date: 20210206 |
|
CF01 | Termination of patent right due to non-payment of annual fee |